Evidence map›Paper›PMID 35473474›Full record

ArticleScience progress

Th1 immune maturation effects of

Meixiang Zhou, Shuping Zhou, Kun Han, Jie Zhang, Qingyu Chen, Cong Tian, Hongling Zhu, Mengyi Jiang, Daliu Min

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Meixiang ZhouDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Shuping ZhouDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Kun HanDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Jie ZhangDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Qingyu ChenDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Cong TianDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Hongling ZhuDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Mengyi JiangDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.
Daliu MinDepartment of Oncology, 378725Sixth People's Hospital Affiliated to Shanghai Jiaotong University, China.ORCID 0000-0001-9589-4032
Shanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nocardia rubra cell-wall skeleton (Nr-CWS) is reported as an external immunotherapeutic enhancer with the advantage of antitumor effect on human cancers. However, the immune regulatory role of Nr-CWS is not fully illustrated. We studied mouse CD4

Indexed as

Cell Wall SkeletonPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRhodococcusTh1 CellsAnimalsMiceSignal TransductionCell Wall Skeletoncell wall skeleton, NocardiaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCD4+ T cellsNocardia rubra cell-wall skeletonPAX8PI3 K/AktTh1 differentiation

Identifiers

PMID35473474
PMCPMC10450467
OpenAlexW4224983027

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.